Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association

被引：223

作者：

Furie, Karen L.

Goldstein, Larry B.

Albers, Gregory W.

Khatri, Pooja

Neyens, Ron

Turakhia, Mintu P.

Turan, Tanya N.

Wood, Kathryn A.

机构：

来源：

STROKE | 2012年 / 43卷 / 12期

关键词：

AHA Scientific Statements; atrial fibrillation; antithrombotic therapy; stroke prevention; treatment; TRANSIENT ISCHEMIC ATTACK; NORMALIZED RATIO CONTROL; RISK STRATIFICATION; COST-EFFECTIVENESS; PREDICTING STROKE; ANTICOAGULATION THERAPY; RANDOMIZED EVALUATION; DABIGATRAN ETEXILATE; SUBGROUP ANALYSIS; WARFARIN;

D O I：

10.1161/STR.0b013e318266722a

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

100204 [神经病学];

摘要：

[No abstract available]

引用

页码：3442 / 3453

页数：12

共 55 条

[1]

Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation - Pooled analysis of SPORTIF III and V clinical trials [J].

Akins, Paul T. ;

Feldman, Harvey A. ;

Zoble, Robert G. ;

Newman, David ;

Spitzer, Stefan G. ;

Diener, Hans-Christoph ;

Albers, Gregory W. .

STROKE, 2007, 38 (03) :874-880

[2]

[Anonymous], 2010, SUMMARY MINUTES CARD

[3]

[Anonymous], DAB PRAD RISK BLEED

[4]

[Anonymous], DABIGATRAN ETEXILATE

[5]

[Anonymous], FDA DRAFT BRIEFING D

[6]

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [J].

Beasley, B. Nhi ;

Unger, Ellis F. ;

Temple, Robert .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1788-1790

[7]

Blackshear JL, 1996, LANCET, V348, P633

[8]

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].

Connolly, S. ;

Pogue, J. ;

Hart, R. ;

Pfeffer, M. ;

Hohnloser, S. ;

Chrolavicius, S. ;

Yusuf, S. .

LANCET, 2006, 367 (9526) :1903-1912

[9]

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].

Connolly, S. J. ;

Yusuf, S. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. ;

Flather, M. ;

Hart, R. G. ;

Hohnloser, S. H. ;

Joyner, C. ;

Pfeffer, M. ;

Gaudin, C. ;

Blumenthal, M. ;

Marchese, C. ;

Pogue, J. ;

Hart, R. ;

Hohnloser, S. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Budaj, A. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Dorian, P. ;

Flaker, G. ;

Fox, K. A. A. ;

Franzosi, M. G. ;

Goldhaber, S. ;

Golitsyn, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Kozan, O. ;

Lanas, F. ;

Lau, P. ;

Le Heuzey, J. Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipilis, A. ;

Sitkei, E. ;

Swedberg, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078

[10]

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range [J].

Connolly, Stuart J. ;

Pogue, Janice ;

Eikelboom, John ;

Flaker, Gregory ;

Commerford, Patrick ;

Franzosi, Maria Grazia ;

Healey, Jeffrey S. ;

Yusuf, Salim .

CIRCULATION, 2008, 118 (20) :2029-2037

← 1 2 3 4 5 6 →